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Summary
In multiple sclerosis, the immune system attacks the
white matter of the brain and spinal cord, leading to
disability and/or paralysis. Myelin, oligodendrocytes
and neurons are lost due to the release by immune cells
of cytotoxic cytokines, autoantibodies and toxic amounts
of the excitatory neurotransmitter glutamate.
Experimental autoimmune encephalomyelitis (EAE) is
an animal model that exhibits the clinical and patho-
logical features of multiple sclerosis. Current therapies
that suppress either the in¯ammation or glutamate exci-
totoxicity are partially effective when administered at
an early stage of EAE, but cannot block advanced dis-
ease. In a multi-faceted approach to combat EAE, we
blocked in¯ammation with an anti-MAdCAM-1 (muco-
sal addressin cell adhesion molecule-1) monoclonal anti-
body and simultaneously protected oligodendrocytes
and neurons against glutamate-mediated damage with
the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate
(AMPA)/kainate antagonist 2,3-dihydroxy-6-nitro-7-
sulfamoylbenzo(f)quinoxaline (NBQX) and the neuro-
protector glycine±proline±glutamic acid (GPE;
N-terminal tripeptide of insulin-like growth factor).
Remarkably, administration at an advanced stage of
unremitting EAE of either a combination of NBQX and
GPE, or preferably all three latter reagents, resulted in
amelioration of disease and repair of the CNS, as
assessed by increased oligodendrocyte survival and
remyelination, and corresponding decreased paralysis,
in¯ammation, CNS apoptosis and axonal damage. Each
treatment reduced the expression of nitric oxide and a
large panel of proin¯ammatory and immunoregulatory
cytokines, in particular IL-6 which plays a critical role
in mediating EAE. Mice displayed discernible improve-
ments in all physical features examined. Disease was
suppressed for 5 weeks, but relapsed when treatment
was suspended, suggesting treatment must be main-
tained to be effective. The above approaches, which
allow CNS repair by inhibiting in¯ammation and/or
simultaneously protect neurons and oligodendrocytes
from damage, could thus be effective therapies for mul-
tiple sclerosis.
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glycoprotein; MBP = myelin basic protein; NBQX = 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline; NMDA = N-
methyl-D-aspartate; PBS = phosphate-buffered saline; RPAs = RNase protection assays; SDF = stromal cell derived factor;
TGF = transforming growth factor; TNF = tumour necrosis factor; TUNEL = terminal deoxynucleotidyl transferase-
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 Introduction
Multiple sclerosis is a disease in which the immune system
attacks the white matter of the brain and spinal cord, leading
to disability and/or paralysis (Martin and McFarland, 1995;
Wingerchuk et al., 2001). Myelin, oligodendrocytes and
neurons are lost due to an in¯ammatory attack by leukocytes
that in®ltrate the CNS and release cytotoxic cytokines, anti-
CNS autoantibodies and large amounts of the excitatory
neurotransmitter glutamate. The pathways by which ence-
phalitogenic T cells access the CNS have not been fully
delineated, but clearly involve integrin cell adhesion mol-
ecules, which mediate lymphocyte traf®c. A role for a4 and
b7 integrins and their ligand, mucosal addressin cell adhesion
molecule-1 (MAdCAM-1), in the establishment of experi-
mental autoimmue encephalomyelitis (EAE) was demon-
strated by in vivo administration of anti-a4 integrin (Yednock
et al., 1992; Baron et al., 1993; Kanwar et al.,2 0 0 0 b), anti-b7
integrin (Kanwar et al.,2 0 0 0 b) and anti-MAdCAM-1
(Kanwar et al., 2000a) monoclonal antibodies (mAbs),
which diminished the paralysis associated with EAE when
administered early in the disease process. In contrast, anti-
vascular addressin therapy was not effective when adminis-
tered at a late stage of disease (Kanwar et al., 2000a). A
humanized anti-integrin a4 subunit antibody reduced the rate
of new MRI lesion formation in multiple sclerosis, but did not
abolish it altogether (Tubridy et al., 1999).
Integrin-mediated entry of leukocytes into the CNS leads
to markedly elevated concentrations of glutamate, a major
excitatory amino acid neurotransmitter (Stover et al., 1997).
Glutamate receptors of the AMPA (a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionate) and kainate class are ex-
pressed on both neurons and oligodendrocytes, whereas
receptors of the N-methyl-D-aspartate (NMDA) class are
found on neurons. Low concentrations of glutamate, AMPA
and kainate are toxic to oligodendrocytes and neurons in vitro
(Ikonomidou et al., 1996; McDonald et al., 1998). The
AMPA/kainate receptor antagonist 2,3-dihydroxy-6-nitro-7-
sulfamoylbenzo(f)quinoxaline (NBQX) (Sheardown et al.,
1990) inhibits the excitotoxic effects of glutamate on
oligodendrocytes and has been found to ameliorate the
pathogenesis of relapsing-remitting EAE in myelin basic
protein (MBP)-induced Lewis rat and SJL/J mice models of
multiple sclerosis (Pitt et al., 2000; Smith et al., 2000) when
administered at an early stage of disease, but could not block
the disease process permanently.
Insulin-like growth factor-1 (IGF-1) is another neuropro-
tector, which reduces demyelination, lesion size and num-
bers, and slightly reduces the severity of EAE (Liu et al.,
1997; Lovett-Racke et al., 1998). An N-terminal tripeptide
fragment of IGF-1, glycine-proline-glutamic acid (GPE), was
®rst identi®ed as a novel neuroactive peptide by Sara et al.
(1989). It retains some of the neuroprotective effects of IGF-
1, as demonstrated in animal models of hypoxic-ischaemic
brain injury (Guan et al., 1999) and Huntington's disease
(Alexi et al., 1999). GPE was shown to exhibit cross-receptor
activity in that it inhibited glutamate binding to the NMDA
receptor and prevented neuronal death in the hippocampus
injured by NMDA (Saura et al., 1999). Amantadine was
found to reduce the relapse rate in 53 patients with multiple
sclerosis in a double-blind multicentre study, but the results
would need to be repeated with a larger patient cohort to
con®rm the ef®cacy (Plaut, 1987). Other NMDA antagonists
such as memantine (Wallstrom, et al., 1996) and MK801
(Bolton and Paul, 1997) abrogate neurological de®cits, but
not CNS in¯ammation in EAE in rats.
In this study, we investigated whether advanced stage
EAE, which to date has remained intractable to treatment, can
be treated by blockade of the in¯ammatory response with an
anti-MAdCAM-1 mAb, coupled with protection of oligoden-
drocytes and neurons against glutamate damage with a
combination of the AMPA/kainate antagonist NBQX and the
neuroprotector GPE.
Methods
Induction of unremitting EAE
C57BL/6 mice (8±10 weeks old) were injected subcutaneously in
one ¯ank with 300 mg ofmyelin oligodendrocyte glycoprotein 35±55
(MOG35±55) peptide (MEVGWYRSPFSRVVHLYRNGK), synthe-
sized by Chiron Technologies Ltd, Clayton, Australia and emulsi®ed
in complete Freund's adjuvant (CFA) containing 500 mgo f
Mycobacterium tuberculosis H37Ra (DIFCO Laboratories, Detroit,
USA). They also received 500 ng of pertussis toxin (List Biological
Laboratories, CA, USA) in 200 ml phosphate-buffered saline (PBS)
injected intravenously via the tail vein, followed 48 h later by a
second dose. A second injection of MOG peptide was given in the
absence of pertussis toxin one week later in the opposite ¯ank,
according to a previously accepted protocol (Mendel et al., 1995;
Kanwar et al., 2000a).
Treatment of EAE
The incidence of disease using the above induction protocol varied
from 50 to 100%. Only mice that developed EAE were studied.
Antibody (500 mg) was administered into the tail vein (70% of mAb)
and intraperitoneally (30% of mAb) at 10 mg/kg; whereas for the
neuroprotectors (30 mg GPE and 6 mg NBQX), 50% of reagent was
given intraperitoneally and 50% intravenously. `Mock-treated' mice
received either rat IgG at 10 mg/kg (Sigma Co., St Louis, MO, USA)
or PBS. Unless otherwise indicated, ®ve mice were included in each
treatment group for clinical scoring and an additional ®ve mice were
included for analysis of neuropathology. The rat hybridoma MECA-
367 (rat IgG2a) (Berlin et al., 1993), which secretes a mAb against
mouse MAdCAM-1 was provided by Dr Eugene Butcher, Stanford
University, Stanford, CA, and also obtained fromthe American Type
Culture Collection, Rockville, MD. NBQX was obtained from ICN
Biomedicals, Costa Mesa, CA, USA, and GPE from Bachem,
Torrance, CA, USA.
Scoring of disease and disability
Mice were monitored daily and neurological impairment scored
according to the following scale: 0 = no clinical signs of EAE;
1 = limp tail; 2 = partial hind limb paralysis; 3 = complete hind limb
1314 J. R. Kanwar et al.
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 paralysis; 4 = complete hind limb and partial fore limb paralysis;
5 = paralysis extending to diaphragm; 6 = hind and fore limb
paralysis; 7 = death due to EAE. Paralysis extending to the
diaphragm was denoted as dif®culty in remaining upright. Animals
were cared for according to the guidelines of the University of
Auckland Animal Ethics Committee. The daily mean clinical score
for each group is the mean disease score of at least ®ve mice, and
each experiment was repeated at least once, unless otherwise
indicated.
Immunohistochemical analysis of neuropathology
Transverse 10 mm sections made through the spinal cord were
stained with haematoxylin and eosin, and examined by light
microscopy. Data presented in Figs 4±7 are from groups of ®ve
mice at day 75, whose clinical scores are shown in Figs 5±7. Data in
Fig. 4 and Tables 2 and 3 are derived from a separate experiment
involving 10 mice, where two mice were selected for measuring the
apoptotic index and in¯ammation score, at each time point. The
disease scores for these latter mice were comparable to those shown
in Fig. 3. One-mm epoxy sections of cerebrum, cerebellum/
brainstem, cervical, thoracic, lumbar and sacral spinal cord, and
spinal nerve roots were stained with toluidine blue (Sigma) and
examined by light microscopy. A score from 0 to 5 was determined
for in¯ammation, according to established criteria (Moore et al.,
1984; Cross et al., 1994).
An antibody to exon 2 of MBP was raised in a rabbit by coupling a
mouse MBP exon 2 peptide (DSHTRTTHYGSLPQKSQHG-
RTQDENPVVHFFKNCG) to the carrier protein thyroglobulin.
Frozen sections from lumbar spinal cord (10 mm) were immuno-
stained for oligodendrocyte content with an antibody against 2¢3¢-
cyclic nucleotide 3¢-phosphodiesterase (CNPase, Sigma; diluted
1:100); for axonal damage with an antibody against non-phos-
phorylated neuro®lament-H (SM1-32; Sternberger Monoclonals
Incorporated, Lutherville, MA, USA; diluted 1:1000), and for
glutamate receptor subunit 2 (GluR2) content using a mouse mAb
obtained from Zymed Laboratories Inc., Carlton, San Francisco, CA,
USA (diluted 1:1000). Antibody staining was visualized with an
avidin:biotinylated enzyme complex (Vector Laboratories,
Burlingame, CA, USA).
Measurement of cell type speci®c apoptosis
Sections were incubated with ¯uoroisothiocyanate (FITC) linked
TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyur-
idine triphosphate-digoxigenin nick end labelling) (Boehringer-
Mannheim, Mannheim, Germany), and subsequently overnight at
4°C with cell-type-speci®c and anti-mouse caspase-3/CPP32 mAbs,
followed by detection using tetramethyl rhodamine isothiocyanate
(TRITC) conjugated goat anti-mouse immunoglobulin G (IgG) or
anti-rat IgG, or goat anti-rabbit IgG (1:100; Sigma). Slides were
examined under a Nikon Eclipse E600 ¯uorescence microscope
®tted with a DXM1200 digital camera. Analysis of coded sections
was performed by an observer blinded to the treatment, who rated 10
visual ®elds (1.6 mm2) per section of spinal cord at 2503
magni®cation from ®ve sections obtained at different levels of the
spinal cord per animal. Apoptotic oligodendrocytes and neurons
were determined in 0.01 mm2 ®elds at 10003 magni®cation.
Sections were also examined on a Leica TCS 4D confocal
microscope (Leica Microsystems, GmbH, Heidelberg, Germany)
(Kanwar et al., 2001a, b) and compiled from sets of three to ®ve
consecutive single optical sections using Leica ScanwareÔ 4.2A
software (Leica Lasertechnik, GmbH, Heidelberg, Germany).
Alternatively, tissue sections were immunostained by the ABC
(avidin-biotinylated enzyme complex) method using diaminobenzi-
dine (DAB) (Vector Laboratories, Inc., Burlingame, CA, USA), then
brie¯y counterstained with haematoxylin.
Western blot analysis, TUNEL, ELISA, RNAse
protection and anti-MOG35±55 antibody assays
More detailed methods including methods for western blot analysis,
TUNEL, enzyme-linked immunosorbent assay (ELISA), RNase
protection assays (RPAs) and anti-MOG35±55 antibody assays are
provided as online supplementary material.
Statistics
Results were expressed as mean 6 SD. Neuropathological data were
compared using analysis of variance (ANOVA), post hoc tests, t-test
by Bonferroni or Dunnett test for multiple comparisons using Systat
Software version 10.2 (Systat, Software, CA, USA). Statistical
signi®cance was set at P < 0.05.
Results
Blockade of MAdCAM-1 prevents the
development of an unremitting form of EAE
We induced an unremitting form of EAE (Mendel et al.,
1995; Kanwar et al., 2000a) by immunizing C57BL/6 mice
subcutaneously with MOG35±55 peptide emulsi®ed in CFA
containing Mycobacterium tuberculosis H37Ra), and subse-
quently administering pertussis toxin. The ®rst signs of
clinical EAE ensued between days 28 to 35, with a gradual
decrease in the average body weight of mice from 23±24 g to
11 g within 2 weeks (Figs 1, 2 and 3). There was progressive
development of tail and hind limb paralysis from day 35,
which reached a peak at days 42 to 45 (Figs 2 and 3). The
delayed start of disease and high clinical score, which
persisted at the same level for several months, are character-
istic of MOG-induced EAE in the C57BL/6 strain of mice
(Mendel et al., 1995). In con®rmation of a role for the
vascular addressin MAdCAM-1, three intravenous and
intraperitoneal injections of anti-MAdCAM-1 mAb given
on days 35, 37 and 39 (following injection of autoantigen)
completely prevented the induction of EAE such that no overt
clinical symptoms could be observed for 57 days after
suspension of antibody treatment (Fig. 2).
Neuroprotectors suppress but do not prevent the
development of EAE
NBQX given daily for 6 days (days 35±40) following
injection of autoantigen suppressed MOG35±55-induced
EAE for at least 14 days following suspension of treatment
(mean disease score 0.7 6 0.4 compared with 4.1 6 1.5 for
control rat IgG at day 54) but, unlike the results achieved with
anti-MAdCAM-1 mAb treatment, disease severity gradually
Reversal of advanced encephalomyelitis 1315
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 increased 3 days following suspension of treatment (Fig. 2).
GPE also suppressed EAE for at least 14 days following
suspension of treatment (mean disease score 0.7 6 0.4
compared with 4.1 6 1.5 for control rat IgG at day 54) when
given as a short-term treatment for 6 days from day 35
(Fig. 2). However, thereafter disease severity gradually
increased as with NBQX. In summary, each treatment form
was able to inhibit the progression of EAE when administered
early in the course of disease, where the effectiveness of
treatment was anti-MAdCAM-1 mAb > NBQX or GPE. As
monotherapies, only anti-MAdCAM-1 mAb treatment was
able to completely prevent the development of early stage
EAE. Surprisingly, combined treatment with GPE and NBQX
had a synergistic effect, leading to sustained suppression of
disease symptoms for at least the 55 days the animals were
monitored following suspension of treatment (Fig. 2).
However, it did not completely prevent the development of
disease. The triple combination of anti-MAdCAM-1 mAb,
NBQX and GPE, as with anti-MAdCAM-1 mAb alone,
completely prevented the development of disease in all six
mice (Fig. 2). Similar results were obtained in a repeat
experiment.
In summary, there was strong evidence of a therapeutic
effect over time in the different groups of mice
[F(6,615) = 4.2, P = 0.0004], and when the control groups
were compared with all the various treatment groups
[F(1,615) = 24.6, P < 0.0001]. No difference could be
demonstrated in the shape of the therapeutic effect obtained
with the different agents. However, there was strong evidence
of a difference in the rate of change in strength of the
therapeutic effect over time in the treatment groups
[F(4,444) = 16.6, P < 0.0001] with the effects of the
combined treatments differing from those of the monothera-
pies [F(1,444) = 18.9, P < 0.0001], anti-MAdCAM mAb
treatment differing from the GPE and NBQX monotherapies
[F(1,444) = 43.2, P < 0.0001], and some evidence of
GPE + NBQX treatment differing from the triple combination
of GPE + NBQX + anti-MAdCAM-1 mAb [F(1,444) = 3.9,
P = 0.05]. The results of GPE monotherapy could not be
shown to differ from NBQX monotherapy [F(1,444) = 0.33,
P = 0.57].
Simultaneous blockade of integrin and GluRs
ameliorates advanced EAE
We next tested the above mono- and combination therapies
for their ability to combat EAE at an advanced stage in which
mice had suffered from complete hind limb paralysis for
3 weeks. Administration of three injections (beginning on
day 51 after injection of autoantigen) of high dose anti-
MAdCAM-1 mAb when mice had been paralysed for at least
10 days caused initial remission of disease, which was
quickly followed by a gradual and complete relapse after
suspension of treatment (Fig. 3A). NBQX and GPE admin-
istered for 7 days as monotherapies from day 60 caused only
temporary remission and, by day 77, the disease had relapsed
(Fig. 3A). Surprisingly, the combination of NBQX with GPE
appeared to be synergistic as the disease was suppressed
[mean disease score reduced from 3.5 6 0.7 at day 59 (before
treatment) to 1.2 6 0.7 at day 69 (3 days after suspension of
treatment)] for 24 days following suspension of treatment.
Further, simultaneous administration of anti-MAdCAM-1
mAb, NBQX and GPE also delivered sustained protection
[mean disease score reduced from 3.5 6 0.5 at day 59 (before
Fig. 1 Changes in average body weight associated with the progression of EAE and remission following therapy. Anti-MAdCAM-1 mAb
MECA-367 was administered eight times on alternate days 60 to 74 (arrowed), whereas neuroprotectors (30 mg GPE; and 6 mg NBQX)
were given daily for 18 days (days 60 to 78; dotted line box). Data represent means 6 SD (n = 5). For clarity, the time intervals on the
x-axis are not drawn to scale, but are recorded in either days or weeks, where numbering refers to days.
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 treatment) to 0.8 6 0.2 at day 69 (3 days after suspension of
treatment)] (Fig. 3A). In summary, there was strong evidence
of a difference in the shape of the therapeutic effect over time
in the treatment groups [F(5,503) = 5.7, P < 0.0001] with the
results obtained with the rat IgG control differing from those
obtained with the therapeutic agents [F(1,503) = 25.6,
P < 0.0001], combined treatments differing from mono-
therapies [F(1,503) = 20.7, P < 0.0001], and anti-MAdCAM-
1 mAb monotherapy differing from GPE and NBQX
monotherapies [F(1,503) = 18.3, P < 0.0001]. Neither the
GPE and NBQX monotherapies nor the 2 combinations
(GPE+NBQX and GPE+NBQX+anti-MAdCAM-1 mAb)
could be shown to differ from one another [F(1,503) = 1.2,
P = 0.28 and F(1,503) = 0.14, P = 0.71, respectively].
In a repeat experiment, the various treatment regimes were
administered for 18 days from day 60 (Fig. 3B).
Administration of eight injections (beginning on day 60
after injection of autoantigen) of high dose anti-MAdCAM-1
mAb when mice had been paralysed for at least 20 days
caused only slight remission of disease, which again was
quickly followed by a gradual and complete relapse after
suspension of treatment (Fig. 3B). NBQX and GPE admin-
istered as monotherapies for 18 days from day 60 again
moderately ameliorated disease (NBQX, mean clinical score
1.8 6 0.4 at day 69; GPE mean clinical score 1.8 6 0.8 at
day 69) until days 98 and 77, respectively (Fig. 3B).
However, the triple [NBQX + GPE + anti-MAdCAM-1
mAb (mean clinical score 0.8 6 0.6 at day 69)] and double
[NBQX + GPE (mean clinical score 1.3 6 0.4 at day 69)]
treatments were again more effective at ameliorating disease
but, as with the other treatments, disease eventually relapsed.
There was strong evidence of a difference in the shape of the
therapeutic effect over time in the groups [F(6,615) = 5.7,
P < 0.0001], with control groups differing from the active
therapeutic treatments [F(6,615) = 21.5, P < 0.0001], com-
bined treatments differing from monotherapies
[F(6,615) = 4.6, P = 0.03], and anti-MAdCAM mAb
treatment differing from GPE and NBQX monotherapies
[F(6,615) = 6.3, P = 0.01]. No difference could be shown
between the two combinational treatments, or between the
GPE and NBQX monotherapies [F(6,615) = 0.18, P = 0.67
and F(1,615) = 0.02, P = 0.90, respectively]. In summary,
NBQX and GPE monotherapies that prevent glutamate
excitotoxicity appear more effective than anti-cell adhesion
reagents at treating advanced stage demyelinating disease,
whereas anti-cell adhesion reagents are more effective at
preventing early disease. The disease returned in all cases
following suspension of treatment, suggesting that therapy
must be maintained to prevent relapse. No mice died in any of
the different treatments, suggesting that the treatment proto-
cols are safe and effective at the doses employed.
Mice experience a weight gain following
therapy
Mice experienced a weight gain following treatment, which
correlated with the ef®cacy of the particular treatment
regime, where the weight of mice receiving the triple
treatment (mean average body weight 21.6 6 6.9 compared
with 13.2 6 4.3 for the rat IgG control group at day 119) or
double treatment (GPE + NBQX, mean average body weight
20.8 6 4.8) increased by >50% (Fig. 1).
Disability scores con®rm the relative ef®cacies
of the different treatment regimes
We sought to determine how signs of disability, scored using
a previously developed disability scale (Villoslada et al.,
2000) correlated with each treatment regime. Disability
Fig. 2 Neuroprotectors and cell adhesion blockade with an anti-MAdCAM-1 antibody attenuate the early development of EAE. For
monotherapies, anti-MAdCAM-1 mAb MECA-367 was administered thrice on alternate days 35, 37 and 39 (arrowed), whereas
neuroprotectors (30 mg GPE and 6 mg NBQX) were given daily for 6 days (days 35 to 40; dotted line box). For clarity, the time intervals
on the x-axis are not drawn to scale, but are recorded as either days or weeks where numbering refers to days. The experiment was
repeated with similar results with ®ve mice in each group. For statistical analysis, please refer to Results.
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 scores correlated with the clinical scores of paralysis
(Table 1). Treated animals displayed discernible improve-
ments in alertness, spontaneous mobility, tone, motor func-
tion (grip), sensory function, shiny hair/skin ®rmness and
decreased tremor. The total scores at day 75 were 3 6 1
(P < 0.001) for NBQX + GPE + anti-MAdCAM-1 mAb,
10 6 3( P < 0.001) for NBQX + GPE, 19 6 3( P < 0.001) for
anti-MAdCAM-1 mAb, 10 6 2( P < 0.001) for GPE, and
30 6 4( P > 0 .05) for NBQX, compared with 35 6 3 for rat
IgG treated control mice. The relatively high score for NBQX
was consistent with a short relapse for NBQX treated mice at
this time point (Fig. 3B), whereas scores preceding and after
the relapse were similar to those achieved with GPE. There
was strong evidence of a difference (P < 0.001) in the
disabilityscoresinresponsetothetriple(NBQX+GPE+anti-
MAdCAM-1 mAb) versus the double (NBQX + GPE) treat-
ment, and each of the monotherapies. The double treatment
was statistically different from anti-MAdCAM-1 mAb block-
ade (P < 0.001), but not from GPE treatment alone (P > 0.05).
Simultaneous blockade of integrin and GluRs
reduces CNS apoptosis and axonal damage in
advanced EAE
A neuropathological evaluation of damage to the brain and
spinal cord was carried out to determine the molecular basis
for the therapeutic ef®cacy of the combination treatment
regimes. TUNEL analysis of brain and spinal cord sections
from EAE mice revealed extensive apoptosis, which peaked
Fig. 3 Combination of neuroprotectors GPE and NBQX causes sustained remission of advanced EAE, which is further enhanced by anti-
MAdCAM-1 antibody blockade. (A) Anti-MAdCAM-1 mAb MECA-367 was administered thrice on alternate days 51, 53 and 55, or 60,
62 and 64 (arrowed); whereas neuroprotectors were given daily for 7 days (days 60 to 66; dotted line box). (B) Anti-MAdCAM-1 mAb
MECA-367 was administered eight times on alternate days 60 to 74 (arrowed); whereas neuroprotectors (30 mg GPE and 6 mg NBQX)
were given daily for 18 days (days 60 to 78; dotted line box). The symbols used to plot the clinical scores of each treatment regime are as
in (A). For statistical analysis, please refer to Results.
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 at the height of disease severity (day 45) and then subse-
quently declined to a sustained plateau (Fig. 4A). Sections
taken from NBQX + GPE + anti-MAdCAM-1 mAb, and anti-
MAdCAM-1 mAb treated mice at day 75 had substantial
reductions (60%; P < 0.05) in the numbers of apoptotic cells
compared with mice that had been mock treated with either
Fig. 4 Apoptosis in the CNS as assessed by TUNEL staining and immunohistochemistry. (A) Serial sections of the brain and spinal cord
were TUNEL stained to detect cells undergoing apoptosis. The percentage of apoptotic cells was assessed in 10 randomly selected ®elds
to provide the apoptotic index. Arrows refer to antibody administration, whereas the dotted line refers to administration of
neuroprotectors. Data are expressed as a percentage of apoptotic index (AI) and represent mean 6 SD (n = 5). Comparisons between
MAdCAM-1 mAb and GPE+NBQX+MAdCAM-1 mAb treated mice with rat IgG or PBS treated control mice at day 75 were performed
using ANOVA followed by the Bonferroni±Dunnett test for multiple comparisons. Differences in the AI were signi®cant (P < 0.05, as
indicated by asterisk). For clarity, the time interval on the x-axis is not drawn to scale. (B) Double immuno¯uorescence staining with
¯uorescein-linked TUNEL reveals apoptotic neurons and oligodendrocytes. Illustrated are confocal images of serial spinal cord sections
from EAE mice at day 75. TUNEL positive neurons (top six panels) were stained with anti-caspase 3 (A) and anti-neuron-speci®c protein
(NeuN) mAbs (B), and the images merged. TUNEL positive oligodendrocytes (bottom six panels) were stained with an anti-caspase 3 (C)
and anti-CNPase mAb (D) and the images merged (middle three panels). Overlapping stains produce yellow-coloured cells. Scale bars
represent 20 mm.
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 PBSorratIgG.Incontrast,sectionstakenfromNBQX+GPE,
NBQX, and GPE treated mice showed lesser reductions
(~30%; P > 0.05) in the numbers of apoptotic cells (refer to
apoptotic index, Fig. 4A).
Double immuno¯uorescence staining for TUNEL and
cellular markers was able to determine that all cell types
examined in the CNS of EAE mice at day 75 were subject to
apoptosis (Table 2). Thus, 33±37% of oligodendrocytes, 16%
of neurons, 17±27% of CD11+ T cells, and 17±20% of Mac-
1+ macrophages were apoptotic. Apoptotic neurons and
oligodendrocytes expressed the apoptosis effector caspase 3
(Fig. 4B). The triple treatment was very effective in reducing
the apoptosis of oligodendrocytes and neurons, by 83%, and
89%, respectively, with respect to PBS control (P < 0.001)
(Table 2). Anti-MAdCAM-1 mAb and GPE + NBQX effect-
ively inhibited the apoptosis of oligodendrocytes by 62% and
42%, respectively, whereas GPE and NBQX individually
were only slightly effective. In contrast, GPE and NBQX
effectively inhibited the apoptosis of neurons by 56% and
45%, respectively, and together caused 70% inhibition. Anti-
MAdCAM-1 mAb was equally effective, causing 69%
inhibition. As regards T cells, assessment of the affects of
the agents on T cell apoptosis is complicated by the fact that
the triple, double and anti-MAdCAM-1 mAb treatments
Fig. 5 Assessment of axonal damage by measuring levels of abnormally dephosphorylated neuro®lament-H. (A) Axonal dystrophy in
transverse spinal cord sections stained for dephosphorylated neuro®lament-H using the SM1-32 mAb. Sections were prepared from mice
treated with the various reagents as indicated. Magni®cation: 403.( B) Densitometric analysis of western blots of dephosphorylated
neuro®lament-H in spinal cord homogenates. Western blots containing pooled spinal cord homogenates from ®ve representative mice per
treatment group per lane were stained with the SM1-32 mAb (top panel). Clinical scores at day 75 are as indicated. The relative amounts
of dephosphorylated neuro®lament-H in each lane were recorded by densitometry. The order of the homogenates shown in the histograph
is the same for the western blot. (C) Numbers of damaged axonal cells staining for dephosphorylated neuro®lament-H. Data represent the
means + SD. Comparisons between mice treated with therapeutic agents and those treated with control rat IgG at day 75 were performed
by ANOVA followed by the Dunnett test for multiple comparisons and statistical signi®cance indicated as *P < 0.05, **P < 0.001.
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 reduced the overall numbers of T cells in the CNS by 55%,
40% and 47%, respectively. In the case of the triple treatment,
those T cells able to enter the CNS were less apoptotic
(apoptosis reduced by 55%), whereas the other therapies
increased T cell apoptosis by 200±300%. The numbers of
apoptotic Mac-1+ macrophages were too small to make
reliable comparisons. The triple treatment signi®cantly
(P < 0.001) reduced the apoptosis of oligodendrocytes,
neurons and T cells compared with all other therapies.
Axonal damage is a critical feature of multiple sclerosis
lesions. Dephosphorylated heavy chain of neuro®lament-H is
a quantitative molecular marker of demyelinated and
dystrophic axons (Trapp et al., 1998). Immuno-
histochemistry of spinal cord sections (Fig. 5A and C) and
western blot analysis of spinal cord homogenates (Fig. 5B)
Fig. 6 Survival of oligodendrocytes and remyelination. (A) Transverse sections of spinal cord were stained with an antibody against
CNPase to visualize oligodendrocytes within dorsal columns. Sections from a representative mouse treated with the combination of anti-
MAdCAM-1 mAb + NBQX + GPE were compared with those from a normal undiseased mouse. The upper panels are at magni®cation
203 and middle panels at 1003. An anti-CNPase mAb stained section from a rat IgG-treated mouse (lowest panel as indicated,
magni®cation 1003) is included as a control. (B) Enumeration of oligodendrocytes, and assessment of CNPase activity in spinal cord
sections. Western blots containing pooled spinal cord homogenates from ®ve representative mice per treatment group per lane were
stained with an anti-CNPase mAb (top panel). Clinical scores at day 75 are as indicated. The histograph shows enumeration of
oligodendrocytes in dorsal columns of transverse sections of spinal cord stained with an antibody against CNPase. Each bar represents the
average number of oligodendrocytes from two representative mice, with 5±10 sections analysed per mouse. Data represent means + SD.
Comparisons between mice treated with therapeutic agents and those treated with control rat IgG at day 75 were performed by ANOVA
followed by the Bonferroni±Dunnett test for multiple comparisons and statistical signi®cance indicated as *P < 0.05, **P < 0.001.
(C) Assessment of remyelination by staining for exon 2 of MBP. Transverse sections of the spinal cord, as indicated, were immunostained
with an antibody against exon 2 of MBP to visualize areas undergoing remyelination. (D) Assessment of remyelination by western blot
analysis of the expression of exon 2 of MBP in spinal cord homogenates. Western blots containing pooled spinal cord homogenates from
®ve representative mice per treatment group per lane were stained with an anti-exon 2 MBP antibody (top panel). The arrow indicates the
position of the 18 kDa MBP band. Clinical scores at day 75 are as indicated. The relative amounts of exon 2 of MBP in each lane were
recorded by densitometry. The order of the homogenates shown in the histograph is the same for the western blot.
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 prepared at day 75 revealed that the spinal cords of mock-
treated (rat IgG, PBS) EAE mice (disease score 4.5) displayed
a large increase of abnormally dephosphorylated neuro®la-
ment-H (Fig. 5A and B) and contained increased numbers of
damaged axonal cells (Fig. 5C), whereas these variables were
almost undetectable in normal undiseased mice. The levels of
dephosphorylated neuro®lament-H, and numbers of damaged
axonal cells expressing dephosphorylated neuro®lament-H
after treatment largely correlated with the ef®cacy of the
particular treatment regime. For example, the average relative
densities of neuro®lament-H in day 75 spinal cord homo-
genates resolved by western blot analysis were 1.2 6 0.4 for
NBQX + GPE + anti-MAdCAM-1 mAb, 2.2 6 0.4 for
NBQX+GPE,2.360.7foranti-MAdCAM-1mAb,3.260.6
for GPE and 3.5 6 0.6 for NBQX compared with 6.1 6 2.1
for rat IgG and 6.2 6 2.1 for PBS-treated control mice
(Fig. 5B). GPE and NBQX administered individually almost
halved the numbers of axonal cells expressing dephos-
phorylated neuro®lament-H at day 75 and, in combination,
further reduced the number by 30% (P < 0.05) (Fig. 5B),
indicating that glutamate excitotoxicity is a key feature
contributing to axonal damage in MOG-induced EAE. When
axonal damage was assessed, GPE (P < 0.05) and anti-
MAdCAM-1 mAb treatment (P < 0.05), but not NBQX
(P > 0.05), caused a statistically signi®cant reduction in
damage. In accord, there was no statistical difference
(P > 0.05) between GPE alone and the combination of GPE
and NBQX (Fig. 5C). Thus, in this instance, the levels of the
dephosphorylated heavy chain of neuro®lament-H did not
correlate exactly with the level of axonal damage. There was
no signi®cant difference between anti-MAdCAM-1 mAb
treatment and the combination of GPE + NBQX at reducing
axonal damage (P > 0.05) (Fig. 5B and C), as also evidenced
by a reduction in the overall apoptotic index (Fig. 4), despite
the fact that anti-MAdCAM-1 mAb was therapeutically less
effective in reducing the overall clinical score. The triple
treatment (NBQX + GPE + anti-MAdCAM-1 mAb) was
more effective than the double treatment (NBQX + GPE)
(P < 0.05), and each of the monotherapies (P < 0.05). In
summary, the anti-in¯ammatory and neuroprotective agents
described herein act in concert to reduce the degree of axonal
damage, as re¯ected in the attenuated neuropathology, and
clinical symptoms of disease.
Simultaneous blockade of integrin and GluRs
prevents loss of oligodendrocytes and facilitates
repair of the CNS
Oligodendrocyte numbers were enumerated to evaluate the
effects of the different treatment regimes on the loss of
oligodendrocytes. Sections prepared at day 75 were stained
with an antibody against the oligodendrocyte marker CNPase
(Fig. 6A) and oligodendrocytes within the dorsal columns of
5±10 transverse sections were counted (Fig. 6B). Preservation
of oligodendrocyte numbers correlated with the ef®cacy of
the different treatment regimes. For example, the numbers of
oligodendrocytes were 120 6 18 (P < 0.001) for
NBQX + GPE + anti-MAdCAM-1 mAb, 110 6 15
(P < 0.05) for NBQX + GPE, 104 6 15 (P > 0.05) for
NBQX, 102 6 17 (P > 0.05) for anti-MAdCAM-1 mAb,
93 6 14 (P > 0.05) for GPE versus 74 6 10 for control PBS-
treated mice. The results of the triple and double treatments
were statistically different from each other (P < 0.05), and the
triple treatment was signi®cantly different (P < 0.05) from the
monotherapies. The double treatment was statistically differ-
ent from each of the monotherapies (P < 0.05), except for
NBQX (P > 0.05). These results were con®rmed by western
blot analysis to quantitate the amount of CNPase in spinal
Fig. 7 GluR subunit up-regulation is inhibited by therapy.
(A) Transverse sections of the spinal cord were immunostained
with anti-GluR2 mAbs to visualize expression of AMPA
glutamate receptors in control (PBS, rat IgG, normal), and
NBQX + GPE + anti-MAdCAM-1 mAb treated mice.
Magni®cation 1003, except for the sections from PBS-treated
EAE mice, which were photographed under low power (103), and
reveal butter¯y-shaped grey matter that stains speci®cally with the
anti-GluR2 mAb. (B) Western blot analysis of GluR2 subunit
expression in spinal cord homogenates. Homogenates were
derived from mice treated with the different reagents as indicated.
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 cord homogenates (Fig. 6B). We also investigated whether
repair due to remyelination correlated with reduced loss of
oligodendrocytes. Spinal cord sections at day 75 were stained
with an antibody against exon 2 of mouse MBP. Exon 2
containing MBP transcripts (Jordan et al., 1990; Nagasato
et al., 1997) and protein (Kruger et al., 1999) are expressed de
novo during remyelination in rodents and humans. Distinct
patches of remyelinated tissue in both the grey and white
matter of the spinal cord stained with the anti-exon 2 MBP
antibody, where the number of patches correlated with the
ef®cacy of each treatment regime (Fig. 6C; data is provided
for the triple treatment only). Similar results were achieved
by western blot analysis of exon 2 MBP content in spinal cord
homogenates, where the anti-exon 2 MBP antibody detected a
single MBP band of 18 kDa (Fig. 6D). The levels of
expression of exon 2 of MBP correlated with the ef®cacies of
each treatment regime. Remyelination was increased 4±5 fold
by the double and triple treatment regimes.
Combinational therapy suppresses the up-
regulation of ionotropic GluRs
Levels of the GluR subunits 1 and 2 (GluR1 and 2) increase in
the rat spinal cord after in¯ammation (Zhou et al., 2001),
suggesting their up-regulation is an indicator of disease. As
shown in Fig. 7A, large numbers of cell bodies and dendrites
within the grey matter (dorsal and ventral horns, and
intermediate zone) stained for GluR2. Differential staining
Fig. 8 Blockade of integrin and glutamate receptors decreases the expression of proin¯ammatory and anti-in¯ammatory cytokines.
(A) Multiprobe RPA analysis of cytokine mRNA expression in the CNS was performed (see Methods) using the mCK1b, mCK2b and
mCK3b multiprobe template sets. The gel was imaged and the ratio of the protected bands normalized to the mean sum of the protected
bands for mL32 plus GAPDH (glyceraldehyde-3-phosphate dehydrogenase). Data were quanti®ed and are presented as the mean 6 SD
from two different experiments. (B) ELISA of cytokine and nitrite levels. Results were expressed as the mean concentration 6 SD for
IFN-g, TNF-a, IL-6, IL-4, IL-I0, IL-12, IL-5 (pg/ml) and for nitrite (mM), as shown. Data represent means + SD. Comparisons between
mice treated with therapeutic agents and those treated with control rat IgG at day 75 were performed by ANOVA followed by the
Bonferroni±Dunnett test for multiple comparisons, and statistical signi®cance indicated as *P < 0.05, **P < 0.001.
Reversal of advanced encephalomyelitis 1325
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 indicated that ~30% of the positively staining cells were
in®ltrating leukocytes, whereas the rest were neurons. In
contrast, few cell bodies in the spinal cords of undiseased and
NBQX + GPE + anti-MAdCAM-1 mAb treated mice stained
at this level of intensity. Western blot analysis con®rmed the
marked increases in GluR2 expression in the spinal cords of
mock-treated EAE mice versus undiseased mice (Fig. 7B,
compare normal undiseased mice with rat IgG-treated
diseased controls). Treatment with NBQX led to a marked
down-regulation of GluR2 expression, whereas GPE and anti-
MAdCAM-1 mAb reagents had negligible effect (Fig. 7B).
Combinational therapy suppresses in¯ammation
The effect of each treatment form on CNS in¯ammation was
determined by scoring leukocyte in®ltration into spinal cords
at different time points before (day 45) and following (days
60, 65, 70 and 119) treatment (Table 3). As reported
previously (Kanwar et al., 2000a), anti-MAdCAM-1 mAb
treatment rapidly reduced leukocyte in®ltration into the CNS,
such that at day 70 there were few in¯ammatory cells
proximal to the meninges. Surprisingly, the combination of
NBQX and GPE rapidly reduced in¯ammation to a level
similar to that achieved with the anti-MAdCAM-1 mAb,
whereas GPE and NBQX monotherapies had little effect until
day 119. As expected, the combination of all three reagents
was the most effective at reducing CNS in¯ammation, giving
the very low total in¯ammation score of 1 from day 65 of
treatment, compared with 6 to 7 for PBS-treated and rat IgG -
treated controls.
Treatments reduce cytokine accumulation in the
CNS
Local expression of a large panel of cytokines in the CNS at
day 75 was analysed by a non-radioactive RPA using RNA
extracted from spinal cord homogenates (Fig. 8A) and by
ELISA (Fig. 8B) of supernatants of spinal cord lysates. Only
IL-4 (interleukin-4) and TNF-a (tumour necrosis factor-a)
mRNAs were found expressed at readily detectable, but low
levels in the CNS of normal undiseased mice (Fig. 8A).
Levels of all cytokine mRNAs were greatly elevated in the
CNS of diseased mice, in particular those encoding IFN-g
(interferon-g), IL-8, IL-12 and TNF-a, but also the anti-
in¯ammatory cytokine TGF-b (transforming growth factor-
b). The various treatments had variable effects on the
presence of each cytokine RNA. Thus, GPE and NBQX had
little or no affect on IL-5 mRNAs, whereas anti-MAdCAM-1
antibody reduced levels by 50%. Anti-MAdCAM-1 mAbs
and the two combinational treatments reduced IL-10 mRNA
levels to 25±50%. GPE and NBQX in combination were very
effective at inhibiting (by 85%, P < 0.001) levels of TGF-b
mRNAs. Each treatment reduced IL-8 and 12 mRNA levels
by ~60% and 30%, respectively, but the combinations did not
exhibit synergy. In almost every instance, anti-MAdCAM-1
mAb was more effective than GPE and NBQX. The triple
combination was more effective than the other treatments in
inhibiting IL-6, TNF-a, IL-10 and IL-4.
IL-4, IL-6, IL-10, IL-12, TNF-a and IFN-g proteins were
detected at low levels in normal healthy mice by ELISA and
increased markedly in diseased mice by day 75 (Fig. 8B).
Only IL-5 was completely undetectable in healthy mice.
ELISA con®rmed that each treatment was able to reduce the
levels of CNS cytokines in EAE mice at day 75 by 10±95%.
Thus, the levels of IL-12 (65±90%), IL-5 (62±75%), IL- 6
(70±95%) and IL-10 (55±75%) were strongly down-regu-
lated, whereas reductions in IL-4 (10±45%), TNF-a (15±
60%) and IFN-g (30±60%) were less spectacular except in the
case of the triple therapy. The results obtained by RPA and
ELISA were generally comparable in that each treatment
reduced cytokine levels, but the degree of down-regulation of
cytokine mRNAs versus protein did not necessarily correlate
(for example IL-5, IL-12 and IFN-g), which could re¯ect the
labilities of the respective RNA versus protein molecules.
Expression of nitric oxide was dramatically increased in EAE
mice, and signi®cantly reduced in response to all treatments
concomitant with signi®cantly reduced levels of the latter
proin¯ammatory cytokines.
Anti-MOG antibody response
Sera from all EAE mice produced anti-MOG35±55 antibodies
against the immunizing MOG35±55 peptide, which is an
established antibody target in C57BL/6 mice (Huang et al.,
2001) (Fig. 9). GPE and NBQX alone or in combination had
little affect (P > 0.05) on anti-MOG antibody levels despite
their ability to inhibit disease severity, but in accord with the
fact that Ig is not thought to play an important pathogenic role
in MOG35±55 peptide-induced EAE in C57BL/6 mice
(Hjelmstrom et al., 1998). Nevertheless, anti-MAdCAM-1
mAb either alone (P < 0.001) or in combination (P < 0.001)
reduced anti-MOG35±55 antibody levels by 60±70%.
Table 3 In¯ammation status scalea
Treatments In¯ammation
Day
45
Day
60
Day
65
Day
70
Day
119
Totalb
P B S 332226
Rat IgG 3 2 2 3 2 7
G P E 232215
NBQX 3 3 2 2 1 5
GPE + NBQX 2 3 1 1 1 3
MAdCAM-1 3 3 1 0 1 2
GPE + NBQX
+ MAdCAM
330011
aScoring and averaging in two selected animals was determined
from two coded sections, read blindly, from each cord level at
days 45, 60, 65, 70 and 119. bTotal score from day 65.
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 Discussion
Our results demonstrate that short-term antibody blockade of
MAdCAM-1 is able to completely prevent the early devel-
opment of EAE. Anti-MAdCAM-1 mAb treatment blocked T
cell in®ltration into the CNS, and hence prevented the in¯ux
of new in¯ammatory cells that are required to replace those
undergoing apoptosis, as proposed for anti-a4 integrin mAb-
mediated recovery (Hyduk and Karlik, 1998). Thus, anti-
MAdCAM-1 mAb blockade led to a signi®cant reduction in
the overall apoptotic index. In support, lymphocytes in gene
knockout mice de®cient in integrin a4b7, the major receptor
for MAdCAM-1, fail to arrest and adhere to the vasculature
(Wagner et al., 1996). In contrast, short-term GPE and NBQX
monotherapies could only suppress the development of EAE,
such that disease gradually relapsed over several months.
Nevertheless, it was surprising that the combination of GPE
and NBQX synergized so effectively to suppress disease for
almost 2 months. In the treatment of advanced stage EAE,
short-term and prolonged repetitive anti-MAdCAM-1 anti-
body blockade was ineffective and, while NBQX and GPE
monotherapies diminished disease severity, they could not
prevent partial hind limb paralysis. In contrast, the disease
ameliorated in mice treated with a combination of GPE and
NBQX, and/or NBQX + GPE + anti-MAdCAM-1 mAb, such
that the only noticeable disease symptom retained was
slightly ¯accid tails. Notably, the disease relapsed when
treatment was suspended, suggesting treatment must be
maintained to be effective. The latter combinational treat-
ments led to reduced neuropathology, in¯ammation, axonal
damage and loss of oligodendrocytes, and conversely
increased remyelination, and mice regained body weight.
To attempt to explain why the combinational therapies are so
effective, it is necessary to understand the mechanisms
responsible for disease progression. The in¯ammatory insult
leads to secretion of large amounts of glutamate from
activated leukocytes, neurons and microglia (Piani et al.,
1991). Activated immune cells produce glutamate in large
quantities by deamidating glutamine via glutaminase (Werner
et al., 2000). Glutamate excitotoxicity mediated by AMPA/
kainate types of glutamate receptors damages not only
neurons, but also myelin producing oligodendrocytes.
Oligodendrocytes have only the AMPA/kainate glutamate
receptor and are exquisitely vulnerable to glutamate ex-
citotoxicity, whereas neurons have both types of receptor
(Yoshioka et al., 1996; Gill et al., 2000). Thus, NBQX might
be expected to protect both oligodendrocytes and neurons
from glutamate-mediated excitotoxicity by blocking AMPA/
kainate receptors, but alone would not be suf®cient to
completely protect neurons. GPE might provide the added
protection for neurons. In accordance with this theory, Pitt
et al. (2000) demonstrated that NBQX spares axons and
protects oligodendrocytes during the course of EAE; GPE
also prevents neuronal cell death in the hippocampus injured
by NMDA (Saura et al., 1999). GPE has been previously
shown to interact with NMDA-type glutamate receptors
(Bourguignon et al., 1994; Ikeda et al., 1995; Saura et al.,
1999), but most studies report this interaction occurs at mM
concentrations. After an hypoxic±ischaemic acute brain
injury in the rat, administration of neuroprotective doses of
GPE achieve nM levels of GPE in cerebrospinal ¯uid
(P. D. Gluckman, personal communication), suggesting that
NMDA receptor antagonism is not involved in this model. In
EAE, the blood±brain barrier is disrupted allowing the entry
of macromolecules, suggesting administered GPE may reach
the CNS in higher amounts. NBQX and GPE were similarly
effective at reducing the clinical score, and both decreased the
apoptosis of neurons, particularly in combination. It was
surprising that GPE was as effective as NBQX at preventing
the loss of oligodendrocytes, though both agents were weakly
effective unless used in combination. GPE has the ability to
up-regulate the expression of GAD (Sara et al., 1989), which
could help diminish the toxic levels of glutamate accumulat-
ing in the CNS and thereby indirectly prevent loss of
oligodendrocytes. The triple treatment was superior to all
other treatments in reducing the apoptosis of neurons and
oligodendrocytes in the CNS.
Increased concentrations of glutamate have been shown to
induce a dramatic increase in the Na+-dependent glutamate
transporter EAAC1 and concomitant decreases in the trans-
porters GLAST and GLT-1 during EAE in rats. Changes in
glutamate transporters, which may play a critical role in
pathological changes and neuronal dysfunction in EAE, are
suppressed by treatment with NBQX (Ohgoh et al., 2002).
Our results indicate that NBQX is also particularly effective
at suppressing the levels of GluR2 during EAE, which would
otherwise be expected to respond to increased levels of
glutamate.
Fig. 9 Simultaneous blockade of integrin and glutamate receptors
decreased anti-MOG35±55 antibody responses. Reactivity to MOG
was determined by ELISA using serum (1:1000 dilution) from
age-matched non-treated (n = 5) and EAE-affected mice at day 75.
The results are expressed as mean OD values 6 SD. Data
represent means + SD. Comparisons between mice treated with
therapeutic agents and those treated with control rat IgG at day 75
were performed by ANOVA followed by the Bonferroni±Dunnett
test for multiple comparisons and statistical signi®cance indicated
as **P < 0.001 and non-signi®cance as ***P > 0.05.
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 It was surprising that GPE and NBQX synergized to reduce
in¯ammation to levels almost equivalent to that achieved
with anti-MAdCAM-1 mAb therapy. A direct effect of
NBQX and NMDA antagonist on the in¯ammatory response
has already been ruled out by previous studies (Wallstrom
et al., 1996; Pitt et al., 2000; Smith et al., 2000; Werner et al.,
2000) and hence this possibility was not examined here. Thus,
NBQX does not alter the proliferative activity of antigen
primed T cells (Pitt et al., 2000; Smith et al., 2000; Werner
et al., 2000). Similarly, NMDA antagonists do not affect
lymphocyte proliferation or cytokine secretion in response to
encephalitogenic autoantigen (Wallstrom et al., 1996).
However, it has recently been demonstrated that T cells
express high levels of the glutamate ion channel receptor
GluR3. Glutamate triggered T cell adhesion to laminin and
®bronectin, and up-regulated the chemotactic migration of T
cells toward the chemokine SDF-1a (stromal cell derived
factor-1a), which is constitutively expressed in the nervous
system (Ganor et al., 2003). It has been proposed that
glutamate and SDF-1a act in concert to recruit T cells to the
CNS, in accord with the fact that laminin plays a crucial role
in recruiting autoaggressive T cells. It has further been
proposed that NBQX suppresses EAE because not only does
it block glutamate/AMPA receptors expressed on neurons
and glia, but it also blocks AMPA receptors expressed on
encephalitogenic T cellsÐthereby reducing T cell activation.
The ability of NBQX and GPE to reduce in¯ammation may
also re¯ect their abilities to prevent the apoptosis of neurons,
which would otherwise lead to a heightened in¯ammatory
response due to release of autoantigen and a requirement to
clear the damage done. In this scenario, damage to neurons
and oligodendrocytes would be seen to be a major perpetuator
of the in¯ammatory response. Lombardi et al. (2001) have
revealed that AMPA/kainate and NMDA antagonists inhibit
glutamate-stimulated lymphocyte proliferation; thus, NBQX
and GPE may indirectly inhibit in¯ammation. Inhibition of
in¯ammation would lead to lowered levels of glutamate,
which would in itself be bene®cial as low doses of glutamate
are neuroprotective against high toxic doses of glutamate
(Jonas et al., 2001).
Certain proin¯ammatory cytokines have been shown to be
critical to the progression of EAE. At ®rst sight, our results
seem potentially discrepant in that we observed dramatic
increases in all proin¯ammatory cytokines examined in the
spinal cords of EAE mice including IL-1, IFN-g, IL-6, IL-8,
IL-12 and TNF-a but, in addition, immunoregulatory
cytokines that might be expected to attenuate EAE including
IL-10, IL-4 and TGF-b (Samoilova et al., 1998). However,
the concomitant induction of both proin¯ammatory and
immunoregulatory cytokines has been reported to be a feature
of MOG-induced EAE (Okuda et al., 1998a), whereas in
contrast IL-10, IL-4 and TGF-b are not increased in MBP-
induced relapsing EAE (Okuda et al., 1998b). Mice that are
resistant to MOG-induced EAE secrete primarily IL-4/IL-10
and TGF-b, and have decreased levels of IFN-g (Maron et al.,
1999). It has been proposed that the disease course of EAE
may be in¯uenced by the interplay between the proin¯am-
matory and immunoregulatory cytokines (Okuda et al.,
1998a). IL-6 in particular appears to play an obligatory role
in EAE, as anti-IL-6 antibodies reduce the incidence and
severity of EAE in SJL mice immunized with mouse spinal
cord homogenate (Gijbels et al., 1995) and IL-6-de®cient
gene knockout mice are completely resistant to MOG35±55
induced EAE (Eugster et al., 1998). In accord with previous
studies (Diab et al., 1997), we found that IL-6 mRNA and
protein were highly expressed in the spinal cords of mice with
EAE, whereas the spinal cords of healthy controls contained
only trace levels of IL-6 protein. Each of the treatments
strongly decreased the expression of IL-6 in the spinal cords
of EAE mice, which alone might be expected to have a
profound effect on disease remission. All cytokine proteins
were down-regulated in response to each treatment, though
IFN-g and IL-4 were affected to a lesser extent. IL-10 was
similarly down-regulated, suggesting remission was primar-
ily due to the down-regulation of proin¯ammatory cytokines
rather than an altered balance of pro-and anti-in¯ammatory
cytokines. Interestingly although IL-12 expression was
increased in diseased mice and down-regulated during
remission, IL-12 responsiveness is not required in the
pathogenesis of in¯ammatory demyelination in the CNS
(Murphy et al., 2003; Zhang et al., 2003). Our results are in
accord with those of Okuda et al. (1998b), which showed that
mRNA levels for both in¯ammatory cytokines including
interleukin IL-1a, IL-2, IL-6, IFN-g, TNF-a and TNF-b and
immunoregulatory cytokines including IL-4, IL-10 and TGF-
b were up-regulated in EAE and down-regulated in the
recovery phase of EAE. They concluded that the relative
reduction in production of TGF-b or IL-6 in the peripheral
circulation might participate in the induction or remission of
EAE, respectively.
Nitric oxide biosynthesis is elevated in the CNS in multiple
sclerosis and EAE in response to activation of astrocytes,
macrophages and microglia by the proin¯ammatory cyto-
kines IFN-g, TNF-a and IL-1b (Okuda et al., 1995; Parkinson
et al., 1997). Given that nitric oxide is implicated in the
pathology of multiple sclerosis and EAE (MacMicking et al.,
1992; Owens et al., 2002), it is potentially signi®cant that
expression of this detrimental metabolite was dramatically
increased in EAE mice, and signi®cantly reduced in response
to all treatments concomitant with signi®cantly reduced
levels of RNA and/or protein for the latter proin¯ammatory
cytokines.
Autoantibodies against MOG can be found within acute
lesions of human multiple sclerosis and animal EAE, where
they may contribute to the disintegration of myelin sheaths
(Genain et al., 1999). Signi®cant positive correlations have
been found between anti-MOG35±55 antibody levels in EAE
and clinical scores (Costa et al., 2003). None of the treatments
with GPE and NBQX signi®cantly inhibited the levels of anti-
MOG35±55 antibodies, whereas those including anti-
MAdCAM-1 mAb signi®cantly blocked anti-MOG35±55
antibody production. The relevance of these observations to
1328 J. R. Kanwar et al.
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 disease remission is not clear as B cell de®cient mice are still
fully susceptible to MOG35±55 induced EAE (Eugster et al.,
1998; Lyons et al., 1999).
Several subtypes of GluR are widely distributed outside the
CNS in peripheral tissues, but their roles have not been
de®ned (Gill et al., 2000). Thus, the presence of GluR
subtypes was demonstrated in the rat and monkey heart, with
preferential distribution within the conducting system, nerve
terminals and cardiac ganglia. NMDAR 1, GluR 2/3, and
mGluR 2/3 are also present in kidney, liver, lung, spleen and
testis (Gill et al., 2000). The latter might be anticipated to
complicate therapy. However, disability scores correlated
well with the clinical scores of paralysis, such that animals
treated with the combination of NBQX and GPE in the
presence or absence of anti-MAdCAM-1 mAb displayed
discernible improvements in all physical features examined
including alertness, spontaneous mobility, tone, motor func-
tion (grip), sensory function, weight and shiny hair/skin
®rmness. The triple combination afforded the greatest
improvement in the disability scores. No discernible changes
to any of the major organs were detected following autopsy
(data not shown).
In conclusion, we have shown for the ®rst time that a multi-
faceted approach, which inhibits the in¯ammatory cascade
and/or simultaneously protects neurons and oligodendrocytes
from damage, can effectively attenuate advanced stage
demyelinating disease in a chronic progressive model of
multiple sclerosis. It is known that there is relative sparing of
axons in multiple sclerosis, and that the CNS can repair itself
(Lassmann et al., 2001). The results of the multi-faceted
approach have implications for the treatment of multiple
sclerosis, as they suggest it might be possible to signi®cantly
limit ongoing damage so that axons can be repaired.
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